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50 years were less likely to 
have undergone previous ureteroscopy and 









 0.026). Advanced age was associated 













70 years were less likely to undergo 









 0.026). In multivariable 
analyses, being older was associated with 



















 0.006). However, 
addition of age did not improve the 
predictive accuracy of a base model that 
included standard pathological features for 





Being older at the time of RNU was 
associated with decreased survival. This 
finding could be due to a change in the 
biological potential of the tumour cell, a 
decrease in the host’s defence mechanisms, 
or differences in care patterns. Further work 
is needed to improve our understanding of 
UTUC outcomes in this growing segment of 
the population and to develop strategies to 




age, prognosis, urinary tract cancer, 
urothelial carcinoma, survival 
Study Type – Prognosis (case series)




To assess the impact of patient age on 
outcomes after radical nephroureterectomy 





Data were collected on 1453 patients treated 
with RNU at 13 centres. Pathological slides 
were reviewed by dedicated genitourinary 
pathologists according to standardized 
criteria. Age at RNU was analysed both as a 








RNU is the gold standard treatment for high-
risk upper tract urothelial carcinoma (UTUC), 
and improvements in perioperative care 
together with refinements of surgical 
technique have made this a safe and feasible 
operation for an increasing number of 
patients. To our knowledge, the extent to 
which advanced chronological age affects the 
indications for and outcomes of radical 
nephroureterectomy (RNU) has not been 
investigated. Moreover, the effectiveness and 
relative use of RNU in the subgroup of older 
patients remain controversial. Similar to 
bladder cancer, patients might be denied the 
opportunity to receive the most effective 
treatment for their disease, based on 
chronological age alone [1]. In this context, 
we evaluated the association of patient age 
with pathological and long-term oncological 
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outcomes in a large international cohort of 




This was an Institutional Review Board-
approved study with participating sites 
providing necessary institutional data-
sharing agreements before initiation of the 
study. The international collaboration resulted 
from the joined efforts of all involved 
institutions with the main purpose of creating 
a comprehensive quality data repository with 
the potential to be explored widely to seek 
satisfactory answers exploring many different 
research questions on the diagnosis, 
prognostic factors and management of UTUC. 
In all, 13 academic centres worldwide 
provided data. A computerized databank was 
generated for data transfer. After combining 
the data sets, reports were generated for each 
variable to identify data inconsistencies 
and other data integrity problems. Through 
regular communication with all sites, 
resolution of identified anomalies was 
achieved before analysis. Before final 
analysis, the database was frozen and the 
final data set was produced for the present 
analysis.
The present study comprised 1453 patients 
who underwent RNU with ipsilateral bladder 
cuff resection between 1987 and 2007. 
Regional lymphadenectomy was generally 
performed in patients with suspicious lymph 
nodes on preoperative imaging or with 
adenopathies detected during intraoperative 
examination. Extended lymphadenectomy 
was not routinely performed. Neoadjuvant 
and adjuvant chemotherapy regimens were 
administered to 42 (2.9%) and 169 (11.6%) 
patients, respectively.
All surgical specimens were processed 
according to standard pathological 
procedures, and all slides were reviewed 
by dedicated genitourinary pathologists 
according to prospectively defined identical 
criteria. Pathologists were ‘blinded’ to clinical 
outcomes. All specimens were histologically 
confirmed to be UC. Tumours were staged 
according to the American Joint Cancer 
Committee/Union Internationale Contre le 
Cancer TNM classification. Tumour grading 
was assessed according to the 1998 WHO/
International Society of Urologic Pathology 
consensus classification [2]. Lymphovascular 
invasion was defined as the presence of 
tumour cells within an endothelium-lined 
space without underlying muscular walls. The 





and the tumour architecture were also 
assessed in every representative section. 
Tumour necrosis was defined as the presence 
of microscopic coagulative necrosis whereas 
the presence of necrosis on gross examination 
was not included. The extent of tumour 
necrosis was assessed in a semi-quantitative 




40). Tumour necrosis was recorded as absent 





10% of the tumour 
area).
Patients were generally followed every 
3–4 months for the first year after RNU, every 
6 months from the second through to the 
fifth year, and annually thereafter. Follow-up 
consisted of history, physical examination, 
routine blood work and serum chemistry 
studies, urinary cytology, chest radiography, 
cystoscopic evaluation of the urinary bladder, 
and radiographic evaluation of the 
contralateral upper urinary tract. Elective 
bone scans, chest CT, or MRI were performed 
when clinically indicated.
Disease recurrence was defined as local 
failure in the operative site, regional lymph 
nodes, or distant metastasis. Isolated bladder 
cancer was not considered as disease 
recurrence. Cause of death was determined by 
the treating physicians, by chart review 
corroborated by death certificates, or by death 
certificates alone. Death certificates were 
retrieved from the archived death certificates 
and reviewed for cause of death. Attribution 
of cause of death on the death certificate is 
described in two parts. Part I lists death 
caused by (i) immediate cause of death (final 
disease or condition resulting in death) or by 
(ii) underlying cause of death, and part II lists 
other significant conditions contributing to 
death but not resulting in the underlying 
cause given in part I. Information abstracted 
from each death certificate included the date 
of death, and whether UC was noted in either 
part I or II. To reduce bias in attribution 
of cause of death, for the present study 
purposes, only patients who had UC listed in 
part I of the death certificate were considered 
to have died of UTUC. All patients who were 
coded as dead of cancer had previous disease 




30 days of surgery or before discharge) was 
censored at time of death for cancer-specific 
(CS) mortality analyses.
The Fisher’s exact test and the chi-square 
test were used to evaluate the differences 
between categorical variables. Differences in 
age across dichotomous or ranked categories 





and the Kruskal–Wallis tests, respectively. 
Univariate recurrence and survival 
probabilities after RNU were estimated using 
the Kaplan–Meier method and compared 
using the log-rank statistic. Univariate and 
multivariable regression using Cox 
proportional hazards ratio models addressed 
time to recurrence, all-cause (AC) mortality, 
and CS mortality after RNU. In all models, 
proportional hazards assumptions were 
systematically verified using the Grambsch-
Therneau residual-based test. Predictive 
accuracy was quantified with Harrell’s 
concordance index [3,4]. Internal validation 
was performed using 200 bootstrap re-




 values were two-





 values are given with no 




ASSOCIATION OF AGE WITH CLINICAL AND 
PATHOLOGICAL CHARACTERISTICS
The median (range; interquartile range [IQR]) 
interpatient age was 69.7 (27–97; 15) years. 
At the time of RNU, 85 (5.8%), 229 (15.8%), 
416 (28.6%), 523 (36.0%) and 200 (13.8%) 









80 years, respectively. 
The association of age at RNU with 
clinicopathological characteristics is shown 
in Table 1. Being older was significantly 
associated with a history of previous 
ureteroscopic intervention, history of bladder 
cancer, laparoscopic RNU, infiltrative tumour 
architecture, worse Eastern Cooperative 
Oncology Group (ECOG) performance status, 








 0.02). Lymphadenectomy was performed 









 0.001). Adjuvant chemotherapy was 









 0.001). There was no association between 
age at time of RNU and preoperative 
chemotherapy.
ASSOCIATION BETWEEN AGE AS CONTINUOUS 
AND CATEGORICAL VARIABLES AND 
DISEASE OUTCOMES
The mean (median; range; IQR) follow-up was 
61 (48; 0–250; 61) months for patients alive 
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Age (years) as continuous














50 50–59.9 60–69.9 70–79.9






Male 986 (67.9) 68.1 (27.5–97.1) 61 (71.8) 168 (73.4) 308 (74.0) 334 (63.9) 115 (57.5)
Female 467 (32.1) 72.3 (27.0–94.3) 24 (28.2) 61 (26.6) 108 (26.0) 189 (36.1) 85 (42.5)
pT stage: 0.281†
Ta 295 (20.3) 70.2 (31.0–94.3) 20 (23.5) 48 (21.0) 73 (17.5) 118 (22.6) 36 (18.0)
Tis 28 (1.9) 67.0 (32.0–86.1) 1 (1.2) 5 (2.2) 12 (2.9) 7 (1.3) 3 (1.5)
T1 317 (21.8) 68.0 (34.1–90.7) 20 (23.5) 57 (24.9) 95 (22.8) 100 (19.1) 45 (22.5)
T2 269 (18.5) 69.2 (30.0–96.9) 16 (18.8) 47 (20.5) 75 (18.0) 92 (17.6) 39 (19.5)
T3 475 (32.7) 70.0 (27.0–97.1) 26 (30.6) 62 (27.1) 145 (34.9) 179 (34.2) 63 (31.5)
T4 69 (4.7) 72.9 (43.0–89.0) 2 (2.4) 10 (4.4) 16 (3.8) 27 (5.2) 14 (7.0)
History of bladder cancer: 0.003*
Absent 1085 (74.7) 69.0 (27.0–96.9) 74 (87.1) 177 (77.3) 314 (75.5) 379 (72.5) 141 (70.5)
Present 368 (25.3) 71.0 (40.0–97.1) 11 (12.9) 52 (22.7) 102 (24.5) 144 (27.5) 59 (29.5)
Previous endoscopic procedures: 0.023*
Negative 1253 (86.2) 69.0 (27.0–97.1) 78 (91.8) 203 (88.6) 361 (86.8) 441 (84.3) 170 (85.0)
Positive 200 (13.8) 71.0 (31.0–94.3) 7 (8.2) 26 (11.4) 55 (13.2) 82 (15.7) 30 (15.0)
Tumour grade: 0.198*
Low 516 (35.5) 69.4 (30.0–96.9) 37 (43.5) 85 (37.1) 142 (34.1) 185 (35.4) 67 (33.5)






pNx 841 (57.9) 70.9 (27.5–97.1) 44 (51.8) 121 (52.0) 224 (53.8) 315 (60.2) 137 (68.5)
pN0 472 (32.5) 68.0 (30.7–96.9) 29 (34.1) 89 (38.9) 147 (35.3) 162 (31.0) 45 (22.5)






0 1001 (68.9) 68.0 (27.0–91.0) 67 (78.8) 177 (77.3) 308 (74.0) 348 (66.5) 101 (50.5)
1 358 (24.6) 72.0 (30.7–96.9) 15 (17.6) 44 (19.2) 85 (20.4) 137 (26.2) 77 (38.5)
2 85 (5.8) 74.4 (37.3–90.0) 2 (2.4) 7 (3.1) 20 (4.8) 36 (6.9) 20 (10.0)
3 9 (0.6) 64.1 (48.6–97.1) 1 (1.2) 1 (0.4) 3 (0.7) 2 (0.4) 2 (1.0)
Ethnicity: 0.004†
White 1194 (82.2) 70.1 (27.0–97.1) 66 (77.6) 175 (76.4) 341 (82.0) 439 (83.9) 173 (86.5)
Black 36 (2.5) 69.5 (30.0–85.0) 6 (7.1) 4 (1.7) 8 (1.9) 10 (1.9) 8 (4.0)
Pacific Islander/Asian 223 (15.3) 67.0 (36.0–89.0) 13 (15.3) 50 (21.8) 67 (16.1) 74 (14.1) 19 (9.5)
Lymphovascular invasion: 0.063*
Absent 1104 (76) 69.0 (30.0–97.1) 64 (75.3) 186 (81.2) 319 (76.7) 383 (73.2) 152 (76.0)






Papillary 1066 (73.4) 68.7 (27.0–97.1) 72 (84.7) 180 (78.6) 313 (75.2) 358 (68.5) 143 (71.5)
Infiltrative 387 (26.6) 71.4 (34.1–91.0) 13 (15.3) 49 (21.4) 103 (24.8) 165 (31.5) 57 (28.5)
Procedure type: 0.006*
Open 1128 (77.6) 69.0 (27.0–97.1) 64 (75.3) 185 (80.8) 341 (82.0) 397 (75.9) 141 (70.5)
Laparoscopic 325 (22.4) 71.1 (32.0–94.3) 21 (24.7) 44 (19.2) 75 (18.0) 126 (24.1) 59 (29.5)
Tumour necrosis: 0.278*
Absent 1089 (74.9) 69.5 (27.0–96.9) 65 (76.5) 179 (78.2) 310 (74.5) 386 (73.8) 149 (74.5)
Present 364 (25.1) 70.0 (37.3–97.1) 20 (23.5) 50 (21.8) 106 (25.5) 137 (26.2) 51 (25.5)
Tumour location: 0.107*
Renal pelvis 958 (65.9) 69.0 (27.0–96.9) 64 (75.3) 158 (69.0) 271 (65.1) 330 (63.1) 135 (67.5)






Negative 1035 (71.2) 69.1 (27.0–97.1) 67 (78.8) 171 (74.7) 289 (69.5) 369 (70.6) 139 (69.5)






Negative 1249 (86.0) 70.0 (27.5–97.1) 70 (82.4) 193 (84.3) 346 (83.2) 456 (87.4) 184 (92.0)
Positive 203 (14.0) 66.0 (27.0–93.0) 15 (17.6) 36 (15.7) 70 (16.8) 66 (12.6) 16 (8.0)
 
*Mann–Whitney test; †Kruskal–Wallis test.
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at last follow-up. Actuarial recurrence-free 
estimates at 2, 5, and 10 years after RNU were 
73%, 69%, and 66%, respectively. Actuarial 
AC survival estimates at 2, 5, and 10 years 
after RNU were 73%, 61%, and 47%, 
respectively. Actuarial CS survival (CSS) 
estimates at 2, 5, and 10 years after RNU were 
79%, 72%, and 69%, respectively.
In univariate analyses, age was significantly 
associated with AC and CS mortality, but not 
disease recurrence (Table 2). In univariate 
Cox regression analyses, being older was 


























In multivariable analyses controlling for the 
effects of tumour stage, grade, lymph node 
status, and lymphovascular invasion, age was 
















 0.004). Subgroup analysis in patients who 
did not undergo lymphadenectomy did not 
change the statistical significance of these 
associations.
To further investigate the significant 
relationship between age at the time of 
RNU and AC and CS mortality, similar Cox 
regression analyses were performed 
controlling for the effects of the same 
cofactors as the previous models, but 
including age as a categorical variable. In 











































 0.001) were significantly associated with 
AC and CS mortality, respectively (Table 3).
The predictive accuracy of age as continuous 
variable for prediction of disease recurrence, 
AC survival, and CSS was 52.3%, 59.2%, and 
55.9%, respectively. The predictive accuracies 
of age as a categorical variable for prediction 
of AC and CS mortality were 57.9%, and 
54.3%, respectively (Fig. 1). The addition of 
age as categorical variable did not improve 
the predictive accuracies of the base model 
that comprised pathological stage, grade, 
lymphovascular invasion, and lymph node 





Compared with other cancers, there is little 
data on the impact of age on patterns of care 
and outcomes of patients with UTUC. In the 
present study, 6% of patients treated with 
RNU were aged 
 
<50 years and 14% were aged 
>80 years. Being older was associated with a 
history of previous ureteroscopy, history 
of bladder cancer, laparoscopic RNU, 
infiltrative tumour architecture, worse ECOG 
performance status and female gender. 
TABLE 2 Univariate and multivariable Cox regression analyses predicting disease recurrence, AC survival and CSS in 1453 patients treated with RNU for UTUC
Variable
Disease recurrence AC survival CSS
Univariate Multivariable Univariate Multivariable Univariate Multivariable 
HR P HR P HR P HR P HR P HR P
pT stage <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
T1 vs Ta/Tis 2.85 <0.001 2.14 0.02 1.45 0.03 1.21 0.3 2.75 0.004 2.13 0.030
T2 vs Ta/Tis 6.76 <0.001 4.62 <0.001 2.37 <0.001 1.96 <0.001 7.16 <0.001 5.10; <0.001
T3 vs Ta/Tis 15.28 <0.001 8.66 <0.001 4.19 <0.001 3.13 <0.001 16.31 <0.001 9.82 <0.001
T4 vs Ta/Tis 52.36 <0.001 21.34 <0.001 12.28 <0.001 6.58 <0.001 52.55 <0.001 21.28 <0.001
LVI 3.31 <0.001 1.29 0.03 2.57 <0.001 1.40 0.002 3.55 <0.001 1.38 0.01
Tumour grade 5.15 <0.001 2.50 <0.001 2.37 <0.001 1.56 <0.001 4.72 <0.001 2.20 <0.001
Lymph node status <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Nx vs N0 1.09 0.5 1.54 <0.001 1.37 0.002 1.61 <0.001 1.21 0.2 1.65 <0.001
Npositive vs N0 4.97 <0.001 2.29 <0.001 3.46 <0.001 1.77 <0.001 5.03 <0.001 2.21 <0.001
Age 1.01 0.054 1.01 0.3 1.03 <0.001 1.03 <0.001 1.02 <0.001 1.02 0.004
LVI, lymphovascular invasion; Nx, lymphadenectomy not performed.
TABLE 3 Univariate and multivariable Cox regression analyses of age as a categorical variable predicting 




with age as categorical 
variable 
HR P HR P
Age predicting AC survival <0.001 <0.001
50–59 vs ≤50 years 0.97 0.9 0.92 0.7
60–69 vs ≤50 years 1.57 0.04 1.52 0.06
70–79 vs ≤50 years 1.93 0.003 1.78 0.01
≥80 vs ≤50 years 2.68 <0.001 2.51 <0.001
Age predicting CSS 0.02 <0.001
50–59 vs ≤50 years 0.85 0.6 0.81 0.5
60–69 vs ≤50 years 1.30 0.3 1.30 0.3
0–79 vs ≤50 years 1.19 0.5 1.09 0.8
≥80 vs ≤50 years 1.69 0.03 1.63 0.04
All models corrected for pT stage, lymphovascular invasion, tumour grade and lymph node status.
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Elderly patients were less likely to undergo 
lymphadenectomy or receive postoperative 
chemotherapy for advanced stage disease. 
Most importantly, age was an independent 
predictor of AC and CS mortality.
Being older was associated with CS mortality, 
but not disease recurrence, after controlling 
for the effects of standard pathological 
features. Reasons for this could be a change 
in the biological potential of the tumour 
cell or a decrease in the host’s defence 
mechanisms with advancing age, or even a 
detrimental effect of differences in care 
patterns in elderly compared with younger 
patients. Indeed, in the present study 
advanced age was associated with features of 
advanced disease such as higher rate of 
infiltrative tumour architecture, which has 
been shown to be an ominous independent 
predictor of outcomes after UTUC [5]. In 
addition, while the rate of pTa disease 
decreased, that of pT4 disease increased with 
advancing age.
The higher CS mortality of elderly patients 
treated with RNU compared with younger 
patients may be secondary to suboptimal 
use of RNU (patient selection and delay), 
lymphadenectomy, and/or postoperative 
chemotherapy. It may be that similar to 
bladder cancer, there is a reluctance to 
perform radical surgery in older patients with 
comorbidities resulting in higher tumour 
stage when surgery is eventually performed 
leading to higher CS mortality [1,6]. Thus, the 
association between advanced age and worse 
outcomes in the present study may be a 
selection bias resulting in treatment with RNU 
of elderly patients with relatively more 
advanced disease.
An alternative explanation may be that there 
is a longer delay between diagnosis and 
definitive treatment in elderly patients 
resulting in disease progression and worse 
survival [7–9]. In support of this, in the 
present study older patients were more 
likely to undergo multiple ureteroscopic 
interventions before the decision to perform a 
RNU compared with their younger 
counterparts.
Similar to the reported data on bladder UC, 
elderly patients with UTUC were less likely to 
receive postoperative chemotherapy in the 
presence of advanced disease stage [1,10]. 
This may be partially due to the frailty and 
presence of significant comorbidities in these 
patients, such as impaired renal function and 
cardiac disease. The risk/benefit ratio is 
differently weighted in the elderly compared 
with younger patients. The compromise 
between life years gained vs quality of life 
may be different from the perspective of 
elderly compared with younger patients. 
Similarly, elderly patients were less likely to 
undergo lymphadenectomy. We and others 
have previously shown that nodal status is a 
significant predictor of CS mortality in UTUC 
and that pNx is significantly associated with a 
worse prognosis than pN0 in the subgroup of 
muscle-invasive tumours [11]. Moreover, it 
has also been recently shown that the 
extension of the lymphadenectomy in 
patients with pN0 UTUC seems to be 
associated with CS mortality [12].
The host response might also play a critical 
role in the differential CS mortality rates 
between young and older patients treated 
with RNU for UTUC. In bladder UC, Miller et al. 
[13] reported that the Charlson Index score 
was a strong predictor of increased risk of 
extravesical disease and CS mortality. 
Unfortunately, we did not have data to 
rigorously examine the impact of the 
comorbidities in the present cohort. Weizer 
et al. [14] reported that Karnofsky 
performance status was an independent 
predictor of overall survival on patients aged 
≥70 years presenting with nonmetastatic 
muscle-invasive bladder UC. Moreover, their 
study confirmed that most elderly patients 
were able to undergo definitive treatment 
supporting the point that in elderly patients 
with a good performance status, radical 
surgery offers the best disease control.
There are several limitations in the 
present study. Our results were analysed 
retrospectively and did not control for 
possible selection bias such as presence of 
patient comorbidities. While there was an 
association between age and survival 
endpoints, this association was not true for 
disease recurrence. This could be explained 
by the decrease in the host’s defence 
mechanisms with advancing age and/or 
differences in selection for administration of 
adjuvant chemotherapy. We are unable to 
comment on the extent to which patient age 
factored into the selection of RNU and/or 
perioperative chemotherapy among available 
treatment options for patients presenting 
with high-risk disease. The impact of an age-
based selection bias on treatment outcomes 
FIG. 1. Probability estimates of (A) recurrence-free survival and (B) CSS in 1453 patients treated with RNU for 
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for UTUC is probably substantial, particularly 
given the suspected relative under use of RNU 
for elderly patients. The relative under use of 
chemotherapy in older patients in the present 
series suggests a bias against adjuvant 
treatment in our older patients; the individual 
reasons for this were not available. A careful 
analysis of other factors not addressed in the 
present study, such as the time from invasive 
UTUC diagnosis to the RNU and the impact of 
comorbidities is needed to have a better 
understanding of the effect of age on tumour 
biology and patient survival. Moreover, we did 
not have data on functional status outcomes. 
Such data have not been systematically 
examined and may add to the perspective of 
quality-of-life-adjusted relative survival 
benefits.
Another potential limitation is that the 
patients were treated by various physicians 
and the specimens were evaluated by various 
pathologists over a long period. Although the 
differences in practice patterns across the 
institutions in the present study may affect 
the interpretation of our findings, they are 
reflective of the real world scenario, making 
the conclusions more generalizable. To 
minimize the difference in pathological 
evaluation of the specimens, all specimens 
were reviewed by dedicated genitourinary 
pathologists according to strict 
morphological criteria to standardize 
reproducibility. Furthermore, this is the largest 
reported series of patients treated with 
RNU for UTUC and it is unlikely that large 
prospective randomized trials will be 
organized, due to the relative rarity of this 
disease [15,16]. The limited predictive 
accuracy of our models may suggest that age 
and other important related factors, which 
could not be explored in the present study, 
may play an important role in determining the 
outcomes of this patient population.
In conclusion, the present study suggests 
that delay in definitive treatment, lack of 
lymphadenectomy, and potential under use of 
adjuvant chemotherapy are potential 
modifiable risk factors that could lead to 
improvement of outcomes in elderly patients. 
This together with the efficacy of RNU for 
disease control suggests that elderly patients 
with high-risk UTUC who have an adequate 
performance status should be offered RNU 
earlier. The limitations of the present study do 
not allow us to make recommendations based 
on our data; however, our observations are 
provocative and deserve further attention to 
identify the causes for the worse CS mortality 
in elderly patients and to develop strategies to 
improve cancer control in this population.
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Abbreviations RNU, radical 
nephroureterectomy; (UT)UC, (upper tract) 
urothelial carcinoma; AC, all-cause; CS(S), 
cancer-specific (survival); IQR, interquartile 
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